LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK‐A11

Phosphatidylinositol‐3 kinase (PI3K) inhibitor and histone deacetylase (HDAC) inhibitor have been developed as potential anticancer drugs. However, the cytotoxicity of PI3K inhibitor or HDAC inhibitor alone is relatively weak. We recently developed a novel HDAC/PI3K dual inhibitor FK‐A11 and confirm...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Hiroo, Saijo, Ken, Chikamatsu, Sonoko, Kawamura, Yoshifumi, Ishioka, Chikashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894020/
https://www.ncbi.nlm.nih.gov/pubmed/33274548
http://dx.doi.org/10.1111/cas.14759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894020/
https://www.ncbi.nlm.nih.gov/pubmed/33274548
http://dx.doi.org/10.1111/cas.14759

Ejemplares similares